Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution

Executive Summary

If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.


Related Content

As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability
Lessons From The First Biosimilar MAb Launch In Europe
Which Biosimilars Will Payers Cover? Manufacturer Pedigree Will Be A Factor
Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics
As Onyx Details Come Out, Amgen Turns To Biosimilars
The Name Game: Will Innovators’ Latest Battlefront Kill Biosimilars?
Pfizer Hones Biosimilars Approach For Individual Countries
Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014
Is Merck Less Bullish on Biosimilars?
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts